Form 8-K · Current Report · Filed 2025-06-18
Barbara Weber, M.D., Resigns from Revolution Medicines Board
On June 18, 2025, Barbara Weber, M.D., announced her resignation from the board of directors of Revolution Medicines, Inc., effective immediately prior to the Company's 2025 annual meeting of stockholders.
- Filer
- Revolution Medicines Inc. RVMD · NASDAQ
- Filed
- Accession
- 0001193125-25-142735
- CIK
- 0001628171
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Dr. Weber's resignation is related to the activation of a clinical study under the Company's collaboration with Tango Therapeutics, Inc., and was not due to any disagreement with the Company or its operations.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Market reaction
Close before filing
$39.14
Next session
+1.3%
Since filing
+379.1%
Latest close
$187.53
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVMD reporting the same item, with the next session's move:
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Never miss another RVMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.